Treatment modalities and overall survival outcomes for sinonasal extranodal natural killer/T-cell lymphoma

Leuk Lymphoma. 2021 Mar;62(3):727-730. doi: 10.1080/10428194.2020.1834097. Epub 2020 Oct 15.

Authors

Brandon M Lehrich^{1

2}, Khodayar Goshtasbi², Arash Abiri², Tyler M Yasaka², Peter Papagiannopoulos³, Bobby A Tajudeen³, Elizabeth A Brem⁴, Edward C Kuan²

Affiliations

¹ Medical Scientist Training Program, University of Pittsburgh and Carnegie Mellon University, Pittsburgh, PA, USA.
² Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, CA, USA.
³ Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical Center, Chicago, IL, USA.
⁴ Department of Hematology and Oncology, University of California, Irvine, CA, USA.

PMID: 33054461
DOI: 10.1080/10428194.2020.1834097

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Humans
Killer Cells, Natural
Lymphoma, Extranodal NK-T-Cell* / diagnosis
Lymphoma, Extranodal NK-T-Cell* / therapy
Natural Killer T-Cells*
Nose Neoplasms*

Grants and funding

T32 GM008208/GM/NIGMS NIH HHS/United States